Archives
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-11
- 2018-10
- 2018-07
-
br Conclusions In the current study
2023-10-20

Conclusions In the current study, we found that the exposure of maduramicin to chicken myocardial 1080 6 results in cellular damage and even death via the induction of apoptosis. Maduramicin upregulated the expression of apoptotic genes and activated caspase cascades, which were accompanied by a
-
Introduction Lipoxygenases LOXs are key enzymes that catalyz
2023-10-19

Introduction Lipoxygenases (LOXs) are key enzymes that catalyze the polyunsaturated fatty acids (PUFAs) such as arachidic CK 666 mg (AA), linoleic acid (LA) and others unsaturated fatty acids (Brash, 1999). LOXs are expressed in immune, neural, epithelial, tumor cells and other cells (Claesson, 200
-
In particular we focused our attention on beta adrenergic re
2023-10-19

In particular, we focused our attention on beta2 adrenergic receptors, since their commercial inhibitors are effective in lowering IOP, the primary indication of glaucoma. The hypotensive action of a commercial sequence of beta2 adrenergic receptor siRNA was tested in rabbits. The results confirmed
-
In this article we have outlined the
2023-10-19

In this article, we have outlined the increasing, as yet still circumstantial evidence that the 6TM domains of bacterial ACs might operate as receptors for as yet unknown ligands. Intriguingly, several architectural arguments are also applicable to the 6TM domains of mammalian membrane-bound ACs (mA
-
br Introduction Adenosine deaminase ADA
2023-10-19

Introduction Adenosine deaminase (ADA), which can catalyze the conversion of AD to inosine by removing an amino group, is a key hydrolytic enzyme of purine metabolism (Conway and Cooke, 1939), and plays an important role in an amount of diseases. For example, an increase of ADA activity in serum
-
amantadine hcl mg Pompe disease is accompanied by the defici
2023-10-19

Pompe disease is accompanied by the deficiency of the lysosomal α-1,4-glucosidase that makes the amantadine hcl mg unable to hydrolyze glycogen to glucose, thereby resulting in the accumulation of glycogen in lysosomes, especially in skeletal muscles and cardiac tissues. This accumulation results i
-
As cytosolic acetyl CoA levels
2023-10-19

As cytosolic acetyl-CoA levels in hepatocytes descend, cellular production and concentration of cholesterol go down, a change that is known to be sensed by the Sterol response element binding protein (SREBP)/Cleavage-Activating Protein system, leading to SREBP escort to the Golgi apparatus, cleavage
-
Human lipoxygenase exists in two forms named LOX
2023-10-19

Human 15-lipoxygenase exists in two forms, named 15-LOX-1 (also named 12/15-LOX, 15-LO-1) and 15-LOX-2. Several reports indicate that 15-LOX-1 has a pathophysiological role in respiratory inflammatory diseases, in particular asthma. Increased activity of 15-LOX-1 is displayed in the respiratory trac
-
br Conflict of interest statement br Funding br Acknowledgme
2023-10-19

Conflict of interest statement Funding Acknowledgments We thank the team at Medical and Collider-Accelerator Departments at BNL and for their support at NSRL. We thank Dr. Janice Pluth and Professor Peter O’Neill for useful discussions related to our work. Introduction The DNA damage re
-
Introduction Hepatocellular carcinoma HCC is one of
2023-10-19

Introduction Hepatocellular carcinoma (HCC) is one of the most difficult cancers to treat, and it threatens human health severely [1]. Although various interventions, including surgical operation, radiofrequency ablation, and chemotherapy, have been endorsed, the prognosis of HCC patients remains p
-
Although the earlier studies focused on the antioxidant capa
2023-10-19

Although the earlier studies focused on the antioxidant capacity of tocopherols, ascorbic fty720 australia and carotenoids, then it was noticed that phenolic compounds were more powerful than others (Rice-Evans, Miller, & Paganga, 1996). Phenolic compounds, the most numerous and ubiquitous groups o
-
br MADS box proteins in plants a flourishing
2023-10-19

MADS box proteins in plants, a flourishing family In contrast to animals, homeotic genes in plants do not code for homeodomain-containing proteins, but rather, in almost all cases, for MADS domain proteins. The sequencing of the genome of Arabidopsis thaliana revealed more than 100 putative MADS
-
br Concluding remarks and future perspectives While the
2023-10-19

Concluding remarks and future perspectives While the rational engineering of protein-based switches has yet to be fully developed, emerging empirical rules facilitate the construction of tailor-engineered risedronic acid receptor with custom input and output parameters. Both in the context of mol
-
As an internal control this study
2023-10-18

As an internal control, this study validated many of the known associations between GATA3 and predictive markers. GATA3 was shown to be associated with ER and PR, which are both well-known correlations. GATA3 was also negatively correlated with nuclear grade, which is consistent with our knowledge o
-
VER 155008 sale The major phase trial NCT
2023-10-18

The major phase 2 trial (NCT01343966) enrolled 431 participants with mild to moderate AD who received either low-dose SC crenezumab 300 mg or placebo biweekly (n = 184) or high-dose intravenous crenezumab 15 mg/kg or placebo every 4 weeks (n = 247) for 68 weeks 38, 40. No significant treatment benef
16710 records 286/1114 page Previous Next First page 上5页 286287288289290 下5页 Last page